Summary of Sino Biopharmaceutical Conference Call Company Overview - **Company**: Sino Biopharmaceutical (1177.HK) - **Industry**: Pharmaceutical and Biotechnology Key Points Licensing Agreement - Sino Biopharmaceutical has entered into a licensing agreement with Sanofi for the global rights to rovadicitinib, a first-in-class JAK/ROCK inhibitor - The deal includes upfront payments of **US$135 million**, potential milestone payments of up to **US$1.395 billion**, and tiered sales royalties in the double digits - Ravadicitinib was approved for commercialization in China for myelofibrosis in **February 2026** and is in phase 3 trials for chronic graft-versus-host disease (cGVHD) in China, with FDA approval for phase 2 trials in the US - This agreement marks a significant milestone for Sino Biopharmaceutical in its globalization efforts, as it is the first licensing-out deal with a multinational corporation (MNC) [1][2] Clinical Development and Market Potential - cGVHD and myelofibrosis are relatively small indications in the US, with prevalences of approximately **14,000** and **19,000** respectively - Ravadicitinib shows promising potential as a treatment for cGVHD, with a best overall response (BOR) of **86.4%** compared to **74%-76%** for other therapies, and a failure-free survival rate of **85.2%** at 12 months versus **56%** for belumosudil - The safety profile of rovadicitinib is also favorable, with a discontinuation rate of **4%** compared to **6%-16%** for peers [2] Business Development Strategy - The management indicated a focus on retaining China rights for key therapeutic areas (TAs) such as oncology and hepatitis, while opting to license out global rights for assets like rovadicitinib due to commercial challenges in rare diseases in China - The business development strategy includes: 1. Collaborating with large MNCs for assets with global potential 2. Flexible collaboration modes for early-stage assets 3. Exploring emerging markets for mature assets like biosimilars - Key assets with licensing opportunities are expected to have significant data readouts in **2026** [3] Financial Estimates and Valuation - Earnings estimates for **2025-2028** remain largely unchanged, with an increase in the probability of success (PoLS) for rovadicitinib from **50%** to **100%** - The 12-month target price (TP) for Sino Biopharmaceutical has been adjusted slightly to **HK$8.02** from **HK$7.90** [6][8] Risks and Challenges - Key downside risks include: 1. Broader price cuts on the generics portfolio 2. Delays in regulatory approvals for key products 3. Low returns on R&D investments due to resource allocation issues 4. Below-expectation ramp-up of innovative drugs [8] Market Performance - Current market cap is **HK$107.1 billion** (approximately **US$13.7 billion**) - The stock price is currently at **HK$5.71**, indicating an upside potential of **40.5%** to the target price [10] Additional Insights - The agreement with Sanofi is expected to create commercial synergies with Sanofi's existing GVHD portfolio, which includes products like Sarclisa and Rezurock, generating sales of approximately **€588 million** and **€490 million** respectively in **2025** [1]

Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of French drugmaker Sanofi is seen in Paris, France, January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo [Purchase Licensing Rights, opens new tab]March 4 (Reuters) - Hong Kong-listed Sino Biopharmaceutical [(1177.HK), opens new tab] said on Wednesday its unit has signed an exclusive global licensing ...